In conclusion, this study innovatively constructed a prognostic model for the high- and low-risk groups of prostate cancer BCR by characterizing the signature genes of CASP8+ T cells and explored the clinical applicability of the model, which can help to guide clinical decision-making and provide personalized treatment for patients. This evidence concerns the gene CASP8 and Familial prostate cancer.